

References

S-59

1. CMS Pub. 100-3, Medicare National Coverage Determinations Manual, Implantable Automatic Defibrillators, Section 20.4.
2. Al-Khatib SM, Hellkamp A, Curtis J, et al. Non–Evidence-Based ICD Implantations in the United States. *JAMA*. 2011;305(1):43-49.
3. Barsheshet A, Moss AJ, Huang DT, et al. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. *J Am Coll Cardiol*. 2012 Jun 5;59(23):2075-9.
4. Brenyo A, Goldenberg I, Moss AJ, et al. Baseline functional capacity and the benefit of cardiac resynchronization therapy in patients with mildly symptomatic heart failure enrolled in MADIT-CRT. *Heart Rhythm*. 2012 Apr 17.
5. Tsai V, Goldstein MK, Hsia HH, et al. Age differences in primary prevention implantable cardioverter-defibrillator use in U.S. individuals. National Cardiovascular Data Registry.
6. Knight BP MD, FACC. Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death. UpToDate. 2012.
7. Lambiase PD, Barr C, Theuns D, et.al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. *European Heart Journal*. 2014 March 14;2-10.
8. American Heart Association Rapid Access Journal report; New implanted defibrillator works well without touching heart. American Heart Association. 2013 Aug 26.
9. Rowley C.P., Gold M.R. Subcutaneous Implantable Cardioverter Defibrillator. *Circulation:Arrhythmia and Electrophysiology*. 2012;5:587-593.
10. Hauser R.G. The Subcutaneous Implantable Cardioverter-Defibrillator, Should a patient want one? *Journal of the American College of Cardiology*. 2013 Jan 8;61(1):20-22.
11. NICE interventional procedure guidance 454. Insertion of a subcutaneous implantable cardioverter defibrillator for prevention of sudden cardiac death. National Institute for Health and Care Excellence.
12. Mount Sinai Heart. McGowan T. Subcutaneous Implantable Cardioverter-Defibrillator. Mount Sinai.
13. Aziz S, Leon AR, El-Chami MF. The subcutaneous defibrillator: a review of the literature. *Journal of the American College of Cardiology*. 2014 Apr 22;63(15):1473-1479.
14. Al-Khatib SM, Hellkamp AS, Fonarow GC, et.al. Association between prophylactic implantable cardioverter-defibrillator and survival in patients with left ventricular ejection fractions between 30% and 35%. *JAMA*. 2014 June 4;311(21):2209-2215.
15. InterQual® Level of Care Criteria 2014. Acute Care Adult. McKesson Health Solutions, LLC.
16. Clinical Trials.gov. U. S. National Institutes of Health. S-ICD System Post Approval Study. Cameron Health, Inc. ClinicalTrials.gov Identifier: NCT01736618. Currently recruiting. Last updated May/2015.

17. U.S. Food and Drug Administration. Post Approval Study Plan for the S-ICD® System. Published March 12, 2012.
18. InterQual® Level of Care Criteria 2015. Acute Care Adult. McKesson Health Solutions, LLC. INPT-4.
19. Ganz, LI. General principles of the implantable cardioverter-defibrillator. UpToDate website. 2015.
20. Weinstock J, Selan J, Majithia A. Subcutaneous implantable cardioverter defibrillators. UpToDate. 2014.
21. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Oct 15 2013;62(16):e147-239.
22. Rome BN, Kramer DB, Kesselheim AS. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012. *JAMA*. Jan 22-29 2014;311(4):385-391.
23. Marine JE, Russo AM. Primary prevention of sudden cardiac death in heart failure and cardiomyopathy. UpToDate. Reviewed 09/28/2016.
24. Weinstock J, Selan J, Majithia A. Subcutaneous Implantable Cardioverter Defibrillators. UpToDate. Reviewed 12/04/2015.
25. Marine JE, Russo AM. Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy. UpToDate. Reviewed 03/23/2016.